Antagonist anti-LIF antibody derived from naive human scFv phage library inhibited tumor growth in mice.

ABSTRACT:

Background

Leukemia inhibitory factor (LIF) is a multifunctional member of the IL-6 cytokine family that activates downstream signaling pathways by binding to the heterodimer consisting of LIFR and gp130 on the cell surface. Previous research has shown that LIF is highly expressed in various tumor tissues (e.g. pancreatic cancer, breast cancer, prostate cancer, and colorectal cancer) and promotes cancer cell proliferation, migration, invasion, and differentiation. Moreover, the overexpression of LIF correlates with poor clinicopathological characteristics. Therefore, we hypothesized that LIF could be a promising target for the treatment of cancer. In this work, we developed the antagonist antibody 1G11 against LIF and investigated its anti-tumor mechanism and its therapeutic effica

SUBMITTER: Zhao S 

PROVIDER: S-EPMC11340043 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature